Spectral AI (NASDAQ:MDAI – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11), Zacks reports. The company had revenue of $3.99 million during the quarter, compared to analysts’ expectations of $4.13 million.
Here are the key takeaways from Spectral AI’s conference call:
- Spectral AI said it still expects an FDA response by the end of Q2 2026 for its De Novo application, with a goal of moving quickly toward commercialization of DeepView by the end of 2026.
- The company received $31.7 million in accelerated BARDA funding, which it said supports additional feature development and procurement of up to 30 DeepView devices for burn and trauma settings.
- Q1 revenue was $4.0 million versus $6.7 million a year ago, mainly because the base phase of the BARDA Project BioShield contract wound down. Management said the decline was partly offset by other U.S. government work, including the handheld device program.
- The company highlighted encouraging commercial preparation, including a strong showing at the American Burn Association meeting, expanding international opportunities in the U.K., Australia, and GCC markets, and progress on an outcome study intended to support DeepView’s clinical and economic value.
- Financially, Spectral AI ended the quarter with about $11.7 million in cash, $8.5 million of debt, and reiterated full-year 2026 revenue guidance of approximately $18.5 million, excluding meaningful DeepView product sales.
Spectral AI Stock Performance
Shares of Spectral AI stock traded down $0.16 on Wednesday, hitting $2.00. The company’s stock had a trading volume of 660,560 shares, compared to its average volume of 597,641. The company has a market capitalization of $63.48 million, a price-to-earnings ratio of -6.44 and a beta of 1.16. Spectral AI has a 1 year low of $1.18 and a 1 year high of $3.21. The firm has a fifty day moving average price of $1.69 and a 200-day moving average price of $1.65.
Institutional Trading of Spectral AI
Analysts Set New Price Targets
A number of research analysts have issued reports on the company. Weiss Ratings downgraded Spectral AI from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and set a $3.00 price objective on shares of Spectral AI in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.00.
View Our Latest Stock Report on MDAI
Spectral AI Company Profile
Spectral AI, Inc (NASDAQ: MDAI) is a technology company focused on delivering advanced analytics and insights through the application of machine learning to multi-spectral and hyperspectral data. Its core platform ingests imagery from satellites, aerial drones and ground-based sensors, applying proprietary algorithms to identify patterns and anomalies invisible to the naked eye. The company’s solutions are designed to help clients make more informed decisions in areas such as agriculture, environmental monitoring, infrastructure inspection and resource exploration.
The company offers a cloud-native software-as-a-service (SaaS) platform that enables users to visualize and analyze large volumes of spectral data via customizable dashboards.
Featured Articles
- Five stocks we like better than Spectral AI
- Reading the Stripes: Is The Industrial Recession Over?
- Micron Investors Face a High-Stakes Moment After the Latest Rally
- How Bad Could Tesla’s Cybertruck Recall Be for Shares?
- Dream Finders Homes’ Hostile Bid Creates a Dual Squeeze Play
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.
